Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- National Organization Proposed to Train CRCs: Kyoto Univ. Seminar
January 22, 2001
- Kosei-Rodosho Wants to Settle All Drug Price Issues in 2002 Reform
January 22, 2001
- Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
- SBS, GSK Copromote Antidepressant
January 22, 2001
- Revised GPMSP to Be Enforced from October 1
January 22, 2001
- OTC NEWS IN BRIEF
January 22, 2001
- Santen Markets Betimol for Glaucoma in the US
January 22, 2001
- LDP Hashimoto Group Proposes Copayment of 10% or More for Elderly Healthcare
January 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 22, 2001
- Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
- CPAC Members Fail to Form Consensus on Production, Supply of Blood Preparations
January 22, 2001
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2001
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…